Manidipine-d4
(Synonyms: Franidipine-d4, (±)-Manidipine-d4) 目录号 : GC47597An internal standard for the quantification of manidipine
Cas No.:1189656-59-4
Sample solution is provided at 25 µL, 10mM.
Manidipine-d4 is intended for use as an internal standard for the quantification of manidipine by GC- or LC-MS. Manidipine is a dihydropyridine L- and T-type calcium channel blocker.1,2,3 It inhibits recombinant rabbit L-type (α1Cα2/δβ1a) and human T-type (α1H) calcium channels expressed in Xenopus oocytes and native L-type channels in dissociated guinea pig cardiac ventricular cells (IC50 = 2.6 nM). Manidipine inhibits intracellular calcium increases induced by endothelin-1 in A7r5 rat vascular smooth muscle cells (ED50 = 1 nM) and potassium-induced contraction of isolated dog femoral and portal veins (IC50s = 24 and 2.1 nM, respectively).4,5 In vivo, it lowers blood pressure in spontaneously hypertensive rats (SHRs) when administered at a dose of 10 mg/kg and inhibits left ventricular hypertrophy in rats induced by isoproterenol when administered at a dose of 3 mg/kg.6,7 Formulations containing manidipine have been used in the treatment of hypertension.
1.Furukawa, T., Nukada, T., Miura, R., et al.Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (α1G) expressed in Xenopus oocytesJ. Cardiovasc. Pharmacol.45(3)241-246(2005) 2.Furukawa, T., Nukada, T., Namiki, Y., et al.Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Cav3.1 (α1G), Cav3.2 (α1H), and Cav3.3 (α1I)) expressed in Xenopus oocytesEur. J. Pharmacol.613(1-3)100-107(2009) 3.Tohse, N., Takeda, Y., and Kanno, M.Voltage-dependent modulation of L-type Ca2+ current by manidipine in guinea-pig heart cellsEur. J. Pharmacol.249(2)231-233(1993) 4.Huang, S., Simonson, M.S., and Dunn, M.J.Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cellsAm. Heart J.125(2 Pt 2)589-597(1993) 5.Shibouta, Y., Kitayoshi, T., Kitoh, G., et al.Calcium channel blocking action of franidipine hydrochloride (CV-4093.2HCl) in vitro and in vivoJpn. J. Pharmacol.48(4)463-472(1988) 6.Meguro, K., Aizawa, M., Sohda, T., et al.New 1,4-dihydropyridine derivatives with potent and long-lasting hypotensive effectChem. Pharm. Bull. (Tokyo)33(9)3787-3797(1985) 7.Yoshiyama, M., Takeuchi, K., Kim, S., et al.Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophyJpn. Circ. J.62(1)47-52(1998)
Cas No. | 1189656-59-4 | SDF | |
别名 | Franidipine-d4, (±)-Manidipine-d4 | ||
Canonical SMILES | O=C(OC)C1=C(C)NC(C)=C(C(OC([2H])([2H])C([2H])([2H])N2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)=O)C1C5=CC([N+]([O-])=O)=CC=C5 | ||
分子式 | C35H34D4N4O6 | 分子量 | 614.7 |
溶解度 | Methanol: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6268 mL | 8.134 mL | 16.2681 mL |
5 mM | 0.3254 mL | 1.6268 mL | 3.2536 mL |
10 mM | 0.1627 mL | 0.8134 mL | 1.6268 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet